摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-isoxazolylmethanol | 342024-34-4

中文名称
——
中文别名
——
英文名称
3-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-isoxazolylmethanol
英文别名
[3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]-1,2-oxazol-5-yl]methanol
3-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-isoxazolylmethanol化学式
CAS
342024-34-4
化学式
C15H14N2O4
mdl
——
分子量
286.287
InChiKey
NXNQZLLYEBIZQW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    21
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    81.5
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-isoxazolylmethanol氯化亚砜 作用下, 以 甲苯 为溶剂, 反应 0.5h, 以89%的产率得到5-chloromethyl-3-(5-methyl-2-phenyl-4-oxazolylmethoxy)-isoxazole
    参考文献:
    名称:
    ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF
    摘要:
    公开号:
    EP1357115B1
  • 作为产物:
    描述:
    methyl 3-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-isoxazolecarboxylate 在 二异丁基氢化铝 作用下, 以 四氢呋喃 为溶剂, 反应 0.5h, 以86%的产率得到3-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-isoxazolylmethanol
    参考文献:
    名称:
    ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF
    摘要:
    公开号:
    EP1357115B1
点击查看最新优质反应信息

文献信息

  • Imidazopyridine derivatives as JAK inhibitors
    申请人:Almirall, S.A.
    公开号:EP2338888A1
    公开(公告)日:2011-06-29
    New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    揭示了具有化学结构式(I)的新咪唑吡啶衍生物;以及它们的制备方法,包括它们的药物组合物和它们作为Janus激酶(JAK)抑制剂在治疗中的用途。
  • Five-membered heterocyclic alkanoic acid derivative
    申请人:——
    公开号:US20040063775A1
    公开(公告)日:2004-04-01
    The present invention relates to a compound represented by the formula 1 wherein R 1 is an optionally substituted 5-membered heterocyclic group; X is a bond etc.; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond etc.; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH 2 ) n —Z 1 — (n is an integer of 0 to 8 and Z 1 is a bond etc.) and the like; ring B is a 5-membered heterocycle optionally further having 1 to 3 substituents; W is a divalent saturated hydrocarbon group having 1 to 20 carbon atoms; R 2 is —OH etc., or a salt thereof. A pharmaceutical composition containing this compound is useful as a prophylactic or therapeutic agent of diseases such as diabetes mellitus and the like.
    本发明涉及一种由式1表示的化合物,其中R1是可选择取代的5元杂环基团; X是一个键等; Q是具有1到20个碳原子的双价碳氢基团; Y是一个键等; 环A是一个芳香环,可选择进一步具有1到3个取代基; Z是—(CH2)n—Z1—(n为0到8的整数,Z1是一个键等)等; 环B是一个可选择进一步具有1到3个取代基的5元杂环; W是具有1到20个碳原子的双价饱和碳氢基团; R2是—OH等,或其盐。包含该化合物的制药组合物可用作糖尿病等疾病的预防或治疗剂。
  • Alkanoic acid derivatives process for their production and use thereof
    申请人:——
    公开号:US20040058965A1
    公开(公告)日:2004-03-25
    An alkanoic acid derivative useful as a prophylactic or therapeutic agent of diabetes mellitus, hyperlipidemia, impaired glucose tolerance and the like can be provided by a compound represented by the formula 1 wherein R 1 is an optionally substituted 5-membered aromatic heterocyclic group; X is a bond and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond and the like, ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH 2 ) n —Z 1 — (n is an integer of 1 to 8 and Z 1 is an oxygen atom and the like) and the like; ring B is a pyridine ring optionally further having 1 to 3 substituents, and the like; U is a bond and the like; W is a divalent hydrocarbon group having 1 to 20 carbon atoms; and R 3 is —OH and the like, provided that, when ring B is a benzene ring optionally further having 1 to 3 substituents, U should be a bond, or a salt thereof.
    一种可以用作糖尿病、高脂血症、糖耐量受损等预防或治疗剂的脂肪酸衍生物可以由以下式1所表示的化合物提供,其中R1是可选取代的5-成员芳香杂环基;X是键等;Q是具有1到20个碳原子的二价碳氢基团;Y是键等;环A是一种芳香环,可选择进一步具有1到3个取代基;Z是—(CH2)n—Z1—(n是1到8的整数,Z1是氧原子等)等;环B是吡啶环,可选择进一步具有1到3个取代基等;U是键等;W是具有1到20个碳原子的二价碳氢基团;R3是—OH等;但是,当环B是苯环,可选择进一步具有1到3个取代基时,U应为键,或其盐。
  • 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
    申请人:Takeda Pharmaceutical Company Limited
    公开号:US07179823B1
    公开(公告)日:2007-02-20
    A compound of formula (I) F wherein R1 represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; x represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: —CO—, —CS—, —CR4(OR5)— or —NR6— wherein each of R4 and R6 represents a hydrogen atom or a hydrocarbon group which may be stubstituted, R5 represents a hydrogen atom or a protective group for a hydroxyl group; m represents an integer of 0 to 3; Y represents an oxygen atom, a sulfur atom, or a group of the formula: —SO—, —SO2—, —NR7—, —CONR7— or —NR7CO— wherein R7 represents a hydrogen atom or a hydrocarbon group which may be substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group.
    化合物的式子为(I)F,其中R1代表一个可以被取代的碳氢基团或杂环基团;x代表一个键、一个氧原子、一个硫原子或者一个式子为:—CO—、—CS—、—CR4(OR5)—或—NR6—的基团,其中R4和R6分别代表一个氢原子或者一个可以被取代的碳氢基团,R5代表一个氢原子或者一个羟基的保护基团;m代表一个0到3的整数;Y代表一个氧原子、一个硫原子或者一个式子为:—SO—、—SO2—、—NR7—、—CONR7—或—NR7CO—的基团,其中R7代表一个氢原子或者一个可以被取代的碳氢基团;环A代表一个芳香环,可以有1到3个取代基;n代表一个1到8的整数;环B代表一个含氮的5元杂环,可以有一个烷基的取代基。
  • FIVE-MEMBERED HETEROCYCLIC ALKANOIC ACID DERIVATIVE
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1394154A1
    公开(公告)日:2004-03-03
    The present invention relates to a compound represented by the formula wherein R1 is an optionally substituted 5-membered heterocyclic group; X is a bond etc.; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond etc.; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is -(CH2)n-Z1- (n is an integer of 0 to 8 and Z1 is a bond etc.) and the like; ring B is a 5-membered heterocycle optionally further having 1 to 3 substituents; W is a divalent saturated hydrocarbon group having 1 to 20 carbon atoms; R2 is -OH etc., or a salt thereof. A pharmaceutical composition containing this compound is useful as a prophylactic or therapeutic agent of diseases such as diabetes mellitus and the like.
    本发明涉及一种由式表示的化合物 其中 R1 是任选取代的 5 元杂环基团;X 是键等;Q 是具有 1 至 20 个碳原子的二价烃基;Y 是键等;环 A 是芳香环,可任选进一步具有 1 至 3 个取代基;Z 是-(CH2)n-Z1-(n 是 0 至 8 的整数,Z1 是键等)等;环 B 是 5 元杂环,可任选进一步具有 1 至 3 个取代基;W 是二价饱和杂环,可任选进一步具有 1 至 3 个取代基。环 B 是五元杂环,可选进一步具有 1 至 3 个取代基;W 是具有 1 至 20 个碳原子的二价饱和烃基;R2 是-OH 等、或其盐。含有该化合物的药物组合物可作为糖尿病等疾病的预防或治疗药物。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺